Impact of Behavior Modification Interventions and Lung Cancer Screening on Smoking Cessation in People Living With HIV: A Feasibility Study (NCT04949464)

🧪 Interventions in This Study

• Computed Tomography (PROCEDURE)
• Smoking Cessation Intervention (BEHAVIORAL)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (11 Sites)

• UC San Diego Moores Cancer Center — La Jolla, California
• George Washington University — Washington D.C., District of Columbia
• Moffitt Cancer Center — Tampa, Florida
• Washington University School of Medicine — St Louis, Missouri
• Weill Cornell Medicine - Cornell Clinical Trials Unit — New York, New York
• Mount Sinai Hospital — New York, New York
• Montefiore Medical Center — The Bronx, New York
• The Ohio State University James Cancer Hospital — Columbus, Ohio
• Thomas Jefferson University — Philadelphia, Pennsylvania
• University of Texas M.D. Anderson Cancer Center — Houston, Texas
• Virginia Mason Medical Center — Seattle, Washington

📞 Contact the Study Coordinator

Phone: (212) 659-8551

Email: Keith.Sigel@MSSM.edu

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in HIV Infection

• Gene Therapy in Treating Patients With Human Immunodeficiency Virus-Related Lymphoma Receiving Stem Cell Transplant — La Jolla, California
• Safety, Tolerability, and Efficacy of IL-15 Superagonist (N-803) With and Without Combination Broadly Neutralizing Antibodies to Induce HIV-1 Control During Analytic Treatment Interruption — Birmingham, Alabama
• A Study of Doravirine/Islatravir (DOR/ISL, MK-8591A) for the Treatment of Human Immunodeficiency Virus 1 (HIV-1) Infection in Participants Who Previously Received DOR/ISL (MK-8591A-054) — Birmingham, Alabama
• Baricitinib Curative Repression of HIV-1 — Atlanta, Georgia
• Duo: A Phase IIIb Individual-Level Randomized Controlled Trial of an Integrated Strategy — Los Angeles, California

Explore by condition: All HIV Infection clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Contact the study coordinator using the phone/email above.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.